A new study published in the New England Journal of Medicine has found that the weight loss drug Wegovy may also reduce the risk of stroke and heart attacks. The study, which was conducted by Novo Nordisk, the maker of Wegovy, followed 17,604 adults with obesity or overweight and heart disease for five years. Participants were randomly assigned to receive either Wegovy or a placebo.
The study found that Wegovy users were 20% less likely to experience a major cardiovascular event (MACE), such as a heart attack, stroke, or heart-related death, than those who received the placebo. Wegovy users were also 22% less likely to experience a heart attack and 15% less likely to experience a stroke.
The study’s findings are significant because they suggest that Wegovy may have benefits beyond weight loss. Obesity is a major risk factor for heart disease, and weight loss is one of the best ways to reduce that risk. However, previous studies of weight loss drugs have not shown a clear benefit in reducing the risk of heart disease.
The findings of this study suggest that Wegovy may be a valuable tool for people with obesity or overweight who are at risk for heart disease. Wegovy is currently approved by the FDA for weight loss, but it is not yet approved for the prevention of heart disease. The FDA is expected to review the study’s findings and make a decision about whether to approve Wegovy for the prevention of heart disease in the coming months.
In the meantime, people who are considering using Wegovy should talk to their doctor about the risks and benefits of the drug. Wegovy can have side effects, such as nausea, vomiting, diarrhea, and constipation. It is also important to note that Wegovy is not a magic bullet for weight loss. People who take Wegovy still need to make lifestyle changes, such as eating a healthy diet and exercising regularly, in order to lose weight and keep it off.